logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Tentarix Biotherapeutics Completes Series B Financing Bringing Total Equity And Upfront Deal Consideration To $132 Million

Sep 06, 2023•over 2 years ago

Round Type

series b

San DiegoBiotechnology

Investors

Samsara Bio CapitalVersant VenturesGilead Sciences, Inc.Amplitude Ventures

Description

Tentarix Biotherapeutics, a biotechnology company focused on leveraging its proprietary TentaclesTM platform to discover and develop multi-functional, conditional protein therapeutics, today announced it has raised $35 million in a Series B financing led by Amplitude Ventures with participation from Gilead Sciences, Inc., and founding investors Versant Ventures and Samsara BioCapital.

Company Information

Company

Tentarix

Location

10355 Science Center Drive

San Diego, California, United States

About

Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage powerful synergistic biology. On an unprecedented scale, we are leading a fundamental change in the methods of discovery and engineering of multi-specific biologics.

Related People

2 contacts

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers